IDYA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.927

-37.75%

-0.940

+14.63%

-0.930

+5.68%

Estimates Revision

The market is revising No Change the revenue expectations for IDEAYA Biosciences, Inc. (IDYA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 39.53%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+39.53%

In Past 3 Month

18 Analyst Rating

Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 50.81 USD with a low forecast of 30.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

50.81

High

90.00

Current: 0.000

Low

30.00

Averages

50.81

High

90.00

UBS

assumed

$50

2026-01-07

New

Reason

UBS

Price Target

$50

2026-01-07

New

assumed

Reason

UBS assumed coverage of Ideaya Biosciences (IDYA) with a Buy rating and $50 price target. as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences, Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Truist

Gregory Renza

Buy

maintain

$59 -> $60

2026-01-06

New

Reason

Truist

Gregory Renza

Price Target

$59 -> $60

2026-01-06

New

maintain

Buy

Reason

Truist analyst Gregory Renza raised the firm's price target on Ideaya Biosciences to $60 from $59 and keeps a Buy rating on the shares. Ideaya, a top pick for 2026, is approaching a key near-term catalyst with daro's topline progression free survival readout in first line uveal melanoma in 1Q26, the analyst tells investors in a research note. Strong Phase II data and supportive key opinion leader feedback make the setup attractive, with an 85% probability of success in Good/Best Case scenarios and potential 15%-25% upside, Truist says.

Citi

Buy

maintain

$64

2025-12-12

Reason

Citi

Price Target

$64

2025-12-12

maintain

Buy

Reason

Citi placed an "upside 90-day catalyst watch" on Ideaya Biosciences while keeping a Buy rating on the shares with a $64 price target. The firm likes the share setup into the Phase 2/3 OptimUM-02 trial data, expected in Q1, for metastatic uveal melanoma.

Truist

Buy

initiated

$59

2025-11-24

Reason

Truist

Price Target

$59

2025-11-24

initiated

Buy

Reason

Truist initiated coverage of Ideaya Biosciences with a Buy rating and $59 price target. The company's lead asset, darovasertib/PKCi has a major valuation inflection point approaching from the phase II/III MUM's PFS topline readout that could support accelerated approval, the analyst tells investors in a research note. Based on strong phase II data and positive feedback from key opinion leaders, Truist sees favorable reward-risk profile for the upcoming phase II/III PFS topline readout with roughly 85% probability.

Mizuho

Graig Suvannavejh

Outperform

maintain

$44 -> $46

2025-11-11

Reason

Mizuho

Graig Suvannavejh

Price Target

$44 -> $46

2025-11-11

maintain

Outperform

Reason

Mizuho analyst Graig Suvannavejh raised the firm's price target on Ideaya Biosciences to $46 from $44 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q3 report.

JPMorgan

Overweight

maintain

$74 -> $79

2025-10-23

Reason

JPMorgan

Price Target

$74 -> $79

2025-10-23

maintain

Overweight

Reason

JPMorgan raised the firm's price target on Ideaya Biosciences to $79 from $74 and keeps an Overweight rating on the shares. The firm cites an increased probability of success for darovasertib in the neoadjuvant setting, to 70% from 60%, for the target bump. It estimates peak sales of darovasertib to be $500M in the U.S. alone. JPMorgan sees share upside for Ideaya into the metastatic uveal melanoma update.

Valuation Metrics

The current forward P/E ratio for IDEAYA Biosciences Inc (IDYA.O) is -9.02, compared to its 5-year average forward P/E of -11.43. For a more detailed relative valuation and DCF analysis to assess IDEAYA Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.43

Current PE

-9.02

Overvalued PE

-6.74

Undervalued PE

-16.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.03

Current EV/EBITDA

-4.83

Overvalued EV/EBITDA

-2.43

Undervalued EV/EBITDA

-9.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

89.90

Current PS

124.28

Overvalued PS

184.04

Undervalued PS

-4.24

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IDYA News & Events

Events Timeline

No data

News

8.0

01-06NASDAQ.COM

IDYA Options Offer Attractive Discounts and Yield Boosts

1.0

01-05PRnewswire

IDEAYA to Participate in 44th Annual J.P. Morgan Healthcare Conference

8.0

2025-12-30NASDAQ.COM

IDEAYA Biosciences Options Volume Surges to 9,708 Contracts

People Also Watch

Frequently Asked Questions

What is IDEAYA Biosciences Inc (IDYA) stock price today?

The current price of IDYA is 37.38 USD — it has increased 2.61 % in the last trading day.

What is IDEAYA Biosciences Inc (IDYA)'s business?

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

What is the price predicton of IDYA Stock?

What is IDEAYA Biosciences Inc (IDYA)'s revenue for the last quarter?

IDEAYA Biosciences Inc revenue for the last quarter amounts to 207.83M USD, decreased % YoY.

What is IDEAYA Biosciences Inc (IDYA)'s earnings per share (EPS) for the last quarter?

IDEAYA Biosciences Inc. EPS for the last quarter amounts to 1.33 USD, decreased -321.67 % YoY.

What changes have occurred in the market's expectations for IDEAYA Biosciences Inc (IDYA)'s fundamentals?

How many employees does IDEAYA Biosciences Inc (IDYA). have?

IDEAYA Biosciences Inc (IDYA) has 131 emplpoyees as of January 10 2026.

What is IDEAYA Biosciences Inc (IDYA) market cap?

Today IDYA has the market capitalization of 3.28B USD.